Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 3.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 47,691 shares of the biotechnology company’s stock after acquiring an additional 1,601 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Anika Therapeutics were worth $1,208,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Invenomic Capital Management LP raised its holdings in Anika Therapeutics by 124.6% during the 4th quarter. Invenomic Capital Management LP now owns 210,332 shares of the biotechnology company’s stock worth $4,766,000 after buying an additional 116,679 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Anika Therapeutics by 25.8% during the first quarter. Acadian Asset Management LLC now owns 421,427 shares of the biotechnology company’s stock valued at $10,701,000 after acquiring an additional 86,436 shares during the period. Boston Partners purchased a new stake in shares of Anika Therapeutics in the 1st quarter valued at approximately $733,000. Franklin Resources Inc. boosted its stake in Anika Therapeutics by 16.9% in the 4th quarter. Franklin Resources Inc. now owns 133,611 shares of the biotechnology company’s stock worth $3,028,000 after purchasing an additional 19,276 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Anika Therapeutics by 28.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 65,270 shares of the biotechnology company’s stock worth $1,658,000 after purchasing an additional 14,259 shares in the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analyst Upgrades and Downgrades

ANIK has been the subject of several recent analyst reports. Stephens reaffirmed an “equal weight” rating and issued a $24.00 target price on shares of Anika Therapeutics in a research report on Wednesday, May 29th. Barrington Research restated an “outperform” rating and set a $37.00 price objective on shares of Anika Therapeutics in a research report on Friday, August 9th.

Anika Therapeutics Stock Performance

Anika Therapeutics stock opened at $25.50 on Monday. Anika Therapeutics, Inc. has a twelve month low of $17.44 and a twelve month high of $29.11. The firm has a market cap of $371.97 million, a PE ratio of -4.86 and a beta of 0.83. The firm’s 50 day moving average price is $26.02 and its two-hundred day moving average price is $25.89.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). Anika Therapeutics had a positive return on equity of 0.94% and a negative net margin of 44.45%. The firm had revenue of $41.92 million for the quarter, compared to analysts’ expectations of $39.90 million. During the same quarter in the prior year, the business posted ($0.06) earnings per share. Equities analysts anticipate that Anika Therapeutics, Inc. will post -0.1 EPS for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.